Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 3:16 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2473–2496 of 3,875 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: fast Clear all

Conditions: Diabetes Mellitus, Type 1
Interventions: Fast-acting insulin aspart, iLet™; Drug · Device
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: DNA Repair Disorder, Cockayne Syndrome, Xeroderma Pigmentosum, Trichothiodystrophy
Interventions: Interval History, Physical Examination, ECAB Assessment, Gait Assessment, Specimen Sample Collection; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 6 Months and older
Enrollment: 40 participants
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Type 2 Diabetes
Interventions: Cycloset; Drug
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: 30 Years to 69 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Schizophrenia
Interventions: Functional Adaptation Skills Training (FAST); Behavioral
Lead sponsor: University of California, San Diego; Other
Eligibility: 40 Years and older
Enrollment: 240 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2006
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Parkinson
Interventions: Prism adaptation; Behavioral
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 40 Years to 85 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Double Outlet Right Ventricle, Transposition of the Great Arteries, Truncus Arteriosus, Congenitally Corrected Transposition of the Great Arteries
Interventions: 3D Printed Heart Model; Diagnostic Test
Lead sponsor: Children's National Research Institute; Other
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 3
States / cities: Phoenix, Arizona • Washington D.C., District of Columbia • Philadelphia, Pennsylvania

Conditions: Chronic Pain, Pain
Interventions: Empowered Relief class; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Streptococcal Infections
Interventions: Not listed
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2006
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Coronary Artery Disease, Coronary Stent Occlusion
Interventions: Prolonged inflation, Rapid inflation; Other
Lead sponsor: Central Arkansas Veterans Healthcare System; Federal
Eligibility: 19 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Little Rock, Arkansas

Conditions: Ovarian Cancer
Interventions: Paclitaxel, Cisplatin, Bioferon, Rintatolimod, αDC1 Vaccine, Pembrolizumab, Celecoxib, Debulking Procedure; Drug · Biological · Procedure
Lead sponsor: Kalinski, Pawel, MD, PhD; Other
Eligibility: 18 Years and older · Female only
Enrollment: 28 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Healthy
Interventions: Menu: calories=yes, value pricing=no, Menu: calories=yes, value pricing = yes, Menu: calories=no, value pricing = no; Behavioral
Lead sponsor: University of Minnesota; Other
Eligibility: 16 Years and older
Enrollment: 605 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Healthy
Interventions: Ondansetron, Zofran®; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Acute Respiratory Distress Syndrome, Coronavirus, Hypoxic Respiratory Failure, Hypoxemic Respiratory Failure, Respiratory Complication, Respiratory Insufficiency, Cardiac Dysfunction, Pneumonia, Pulmonary Edema, Pulmonary Inflammation, Respiratory Failure, Cytokine Storm, COVID 19, SARS-CoV-2, Cardiac Event, Cardiac Complication, Cardiac Failure, Cardiac Infarct
Interventions: Pemziviptadil (PB1046), Low Dose (10 mg) Control; Drug
Lead sponsor: PhaseBio Pharmaceuticals Inc.; Industry
Eligibility: 18 Years to 85 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 4
States / cities: Jacksonville, Florida • Sarasota, Florida • Kansas City, Kansas + 1 more

Conditions: Bipolar Disorder
Interventions: Lithium Plus Extended- Release Carbamazepine; Drug
Lead sponsor: Creighton University; Other
Eligibility: 19 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2008
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Disorder of Vitamin B12
Interventions: Vitamin B12; Dietary Supplement
Lead sponsor: University of Florida; Other
Eligibility: 18 Years to 49 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Gainesville, Florida

Conditions: Influenza A, Influenza B
Interventions: QuickVue Influenza A+B; Device
Lead sponsor: Quidel Corporation; Industry
Eligibility: Not listed
Enrollment: 1,381 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 5
States / cities: Phoenix, Arizona • Rochester, New York • Belton, Texas + 2 more

Conditions: Obstructive Sleep Apnea
Interventions: Encore Tongue Suspension System; Device
Lead sponsor: Siesta Medical, Inc.; Industry
Eligibility: 20 Years to 65 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2013
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Diabetic Retinopathy
Interventions: Initiation of treatment of diabetes; Other
Lead sponsor: Temple University; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Normal Physiology
Interventions: In vivo MRS, fMRI, EEG/EOG, Stimulation tasks, NSPRD, Structural MRI; Other
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 18 Years and older
Enrollment: 57 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Diabetes, Metabolic Diseases
Interventions: water-only 24-hour fasting once per week for 6 weeks; Behavioral
Lead sponsor: Intermountain Health Care, Inc.; Other
Eligibility: 30 Years to 69 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 2
States / cities: Murray, Utah • Salt Lake City, Utah

Conditions: Healthy
Interventions: Losartan potassium/Hydrochlorothiazide; Drug
Lead sponsor: Teva Pharmaceuticals USA; Industry
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Fargo, North Dakota

Conditions: Healthy
Interventions: Azithromycin Tablets 600 mg, Zithromax® Tablets 600 mg; Drug
Lead sponsor: Mylan Pharmaceuticals Inc; Industry
Eligibility: 18 Years and older
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2005
U.S. locations: 1
States / cities: Morgantown, West Virginia

Conditions: Healthy
Interventions: metformin HC1 750 mg extended-release tablets; Drug
Lead sponsor: Ranbaxy Laboratories Limited; Industry
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2004
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Healthy Volunteers, Polycystic Kidney, Autosomal Dominant
Interventions: Venglustat GZ/SAR402671; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years to 79 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Miami, Florida

Search by objective public record fields.

Research Study to Look at Fast-acting Insulin Aspart With the Insulin Pump System 'iLet™' in Adults With Type 1 Diabetes

Natural History Study for DNA Repair Disorders

Effect of Cycloset on Glycemic Control When Added to Glucagon-like Peptide 1 (GLP-1) Analogue Therapy

Rehabilitative Training for Older People With Schizophrenia

Prism Adaptation Treatment of Parkinson's Disease

Clinical Impact of Rapid Prototyping 3D Models for Surgical Management

Virtual Empowered Relief for Chronic Pain

Rapid Detection of Group B Streptococcus (Strep)-Labor and Delivery Study

Rapid Inflation/Deflation Compared With Prolonged High-Pressure Balloon Inflation

Intensive Locoregional Chemoimmunotherapy, Intradermal Autologous Alpha-DC1 Vaccines, and Systemic Pembrolizumab for Advanced-Stage Ovarian Cancer

Effect of Nutrition Labeling on Fast Food Choices

Ondansetron HCl Orally Disintegrating Tablets Under Fasting Conditions

Pemziviptadil (PB1046), a Long-acting, Sustained Release Human VIP Analogue, Intended to Provide Clinical Improvement to Hospitalized COVID-19 Patients at High Risk for Rapid Clinical Deterioration and Acute Respiratory Distress Syndrome (ARDS).

Open Label Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) for Rapid Cycling Bipolar Disorder

Evaluation of Holotranscobalamin as an Indicator of Vitamin B12 Absorption

QuickVue Influenza A + B Test Field Study

FAST as a Treatment for Obstructive Sleep Apnea

Evaluation of Progression of Diabetic Retinopathy With Rapid Correction of Hyperglycemia

Development Of Neuroimaging Methods To Assess The Neurobiology Of Addiction

The Fasting II Study

Losartan Potassium/Hydrochlorothiazide 100/25 mg Tablets in Healthy Subjects Under Non-Fasting Conditions

Fasting Study of Azithromycin Tablets 600 mg to Zithromax® Tablets 600 mg

Bioequivalence Study of Metformin HCl 750 mg XR Tablets Under Non Fasting Conditions

Effect of Venglustat in Patients With Renal Impairment